Tobias Fehlmann, Mustafa Kahraman, Nicole Ludwig, Christina Backes, Valentina Galata, Verena Keller, Lars Geffers, Nathaniel Mercaldo, Daniela Hornung, Tanja Weis, Elham Kayvanpour, Masood Abu-Halima, Christian Deuschle, Claudia Schulte, Ulrike Suenkel, Anna-Katharina von Thaler, Walter Maetzler, Christian Herr, Sebastian Fähndrich, Claus Vogelmeier, Pedro Guimaraes, Anne Hecksteden, Tim Meyer, Florian Metzger, Caroline Diener, Stephanie Deutscher, Hashim Abdul-Khaliq, Ingo Stehle, Sebastian Haeusler, Andreas Meiser, Heinrich V Groesdonk, Thomas Volk, Hans-Peter Lenhof, Hugo Katus, Rudi Balling, Benjamin Meder, Rejko Kruger, Hanno Huwer, Robert Bals, Eckart Meese, Andreas Keller
Importance: The overall low survival rate of patients with lung cancer calls for improved detection tools to enable better treatment options and improved patient outcomes. Multivariable molecular signatures, such as blood-borne microRNA (miRNA) signatures, may have high rates of sensitivity and specificity but require additional studies with large cohorts and standardized measurements to confirm the generalizability of miRNA signatures. Objective: To investigate the use of blood-borne miRNAs as potential circulating markers for detecting lung cancer in an extended cohort of symptomatic patients and control participants...
March 5, 2020: JAMA Oncology